S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
S&P 500   4,124.49 (-0.38%)
DOW   32,798.30 (-0.10%)
QQQ   316.26 (-1.39%)
AAPL   164.09 (-0.47%)
MSFT   279.03 (-0.46%)
META   167.47 (-1.63%)
GOOGL   116.01 (-1.10%)
AMZN   136.45 (-2.12%)
TSLA   851.90 (-2.22%)
NVDA   171.04 (-3.87%)
NIO   19.37 (-3.97%)
BABA   91.65 (+0.89%)
AMD   96.30 (-3.77%)
MU   58.50 (-4.80%)
T   18.16 (+0.89%)
CGC   3.01 (-8.23%)
GE   75.95 (+1.02%)
F   15.49 (-1.84%)
DIS   107.67 (-1.32%)
AMC   22.84 (-4.67%)
PYPL   94.35 (-1.98%)
PFE   49.87 (+0.61%)
NFLX   226.45 (-3.02%)
NASDAQ:VIVE

Viveve Medical - VIVE Stock Forecast, Price & News

$0.70
-0.02 (-2.75%)
(As of 08/9/2022 09:57 AM ET)
Add
Compare
Today's Range
$0.70
$0.70
50-Day Range
$0.61
$0.88
52-Week Range
$0.59
$3.08
Volume
200 shs
Average Volume
43,082 shs
Market Capitalization
$7.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

Viveve Medical MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
629.2% Upside
$5.25 Price Target
Short Interest
Healthy
0.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.66) to ($1.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

VIVE stock logo

About Viveve Medical (NASDAQ:VIVE) Stock

Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.

Viveve Medical Price Performance

Shares of VIVE Stock opened at $0.72 on Tuesday. The business's fifty day moving average price is $0.70 and its 200 day moving average price is $0.85. Viveve Medical has a 1-year low of $0.59 and a 1-year high of $3.08.

Viveve Medical (NASDAQ:VIVE - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.67) earnings per share for the quarter. Viveve Medical had a negative return on equity of 132.32% and a negative net margin of 353.45%. The business had revenue of $1.64 million for the quarter. As a group, equities research analysts anticipate that Viveve Medical will post -2.66 EPS for the current year.

Receive VIVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter.

VIVE Stock News Headlines

Viveve Medical (VIVE) to Release Quarterly Earnings on Thursday
Viveve Medical Inc Stock Quote VIVE
Viveve Medical Inc - Stock News
Viveve Medical FY 2021 Earnings Preview
Recap: Viveve Medical Q4 Earnings
Here's what Wall Street expects from Viveve Medical's earnings report
Earnings Preview For Viveve Medical
See More Headlines
Receive VIVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viveve Medical and its competitors with MarketBeat's FREE daily newsletter.

VIVE Company Calendar

Last Earnings
5/12/2022
Today
8/09/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIVE
Previous Symbol
OTCMKTS:PLCSD
Employees
47
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$5.25
Low Stock Price Forecast
$5.25
Forecasted Upside/Downside
+649.8%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-22,030,000.00
Net Margins
-353.45%
Pretax Margin
-329.76%

Debt

Sales & Book Value

Annual Sales
$6.43 million
Book Value
$1.42 per share

Miscellaneous

Free Float
10,031,000
Market Cap
$7.45 million
Optionable
Optionable
Beta
0.63

Key Executives

  • Mr. Scott C. Durbin (Age 53)
    CEO & Director
    Comp: $719.05k
  • Mr. Jim B. Robbins (Age 58)
    Sr. VP of Fin. & Admin. and Principal Accounting & Financial Officer
    Comp: $386.94k
  • Ms. Deborah Ann Jorn M.B.A. (Age 64)
    Sr. Advisor to the CEO & Director
    Comp: $35k
  • Mr. Martin Kerber P.E.
    VP of Research, Devel. & Operations
  • Ms. Jeannie Swindle
    Sr. Director of Corp. Communications
  • Mr. Jeff Sinclair
    VP of International Sales
  • Mr. Gary Kaiser
    VP of Global Marketing
  • Ms. Lori McMillan
    VP of HR
  • Ms. Suzon D. Lommel (Age 64)
    Sr. VP of Regulatory & Quality Affairs













VIVE Stock - Frequently Asked Questions

What is Viveve Medical's stock price forecast for 2022?

0 brokerages have issued 1-year price objectives for Viveve Medical's shares. Their VIVE share price forecasts range from $5.25 to $5.25. On average, they anticipate the company's share price to reach $5.25 in the next year. This suggests a possible upside of 629.2% from the stock's current price.
View analysts price targets for VIVE
or view top-rated stocks among Wall Street analysts.

How has Viveve Medical's stock price performed in 2022?

Viveve Medical's stock was trading at $1.14 at the start of the year. Since then, VIVE stock has decreased by 36.8% and is now trading at $0.72.
View the best growth stocks for 2022 here
.

Are investors shorting Viveve Medical?

Viveve Medical saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 77,800 shares, a drop of 38.3% from the June 30th total of 126,100 shares. Based on an average daily volume of 176,400 shares, the short-interest ratio is presently 0.4 days. Approximately 0.8% of the company's shares are sold short.
View Viveve Medical's Short Interest
.

When is Viveve Medical's next earnings date?

Viveve Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our VIVE earnings forecast
.

How can I listen to Viveve Medical's earnings call?

Viveve Medical will be holding an earnings conference call on Thursday, August 11th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Viveve Medical's earnings last quarter?

Viveve Medical, Inc. (NASDAQ:VIVE) issued its quarterly earnings results on Thursday, May, 12th. The company reported ($0.67) earnings per share (EPS) for the quarter. The business had revenue of $1.64 million for the quarter. Viveve Medical had a negative net margin of 353.45% and a negative trailing twelve-month return on equity of 132.32%.

What other stocks do shareholders of Viveve Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viveve Medical investors own include Corbus Pharmaceuticals (CRBP), Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), SCYNEXIS (SCYX), Western Digital (WDC), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX) and Novavax (NVAX).

When did Viveve Medical IPO?

(VIVE) raised $13 million in an IPO on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How do I buy shares of Viveve Medical?

Shares of VIVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viveve Medical's stock price today?

One share of VIVE stock can currently be purchased for approximately $0.72.

How much money does Viveve Medical make?

Viveve Medical (NASDAQ:VIVE) has a market capitalization of $7.66 million and generates $6.43 million in revenue each year. The company earns $-22,030,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does Viveve Medical have?

Viveve Medical employs 47 workers across the globe.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The official website for the company is www.viveve.com. The company can be reached via phone at (720) 696-8100, via email at ir@viveve.com, or via fax at 720-696-8199.

This page (NASDAQ:VIVE) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.